Prescribing Guanfacine

Why Guanfacine Matters

Guanfacine is a repurposed antihypertensive that has found a real, if narrow, home in psychiatry. It is not a stimulant, it is not a controlled substance, and it does not touch striatal dopamine, which is exactly why it matters. In a field where the most effective ADHD drugs are Schedule II agents with abuse liability, guanfacine offers a non-abusable, refillable alternative that can be handed to patients you would hesitate to give a stimulant.

Be clear-eyed about what it is, though. As monotherapy for uncomplicated ADHD, guanfacine is a third-line drug: its effect size (~0.5) is meaningfully smaller than stimulants (0.8–0.9), it takes weeks to work, and it is not especially well tolerated, since sedation and dropout rates run higher than the psychiatric average. If a patient can safely take a stimulant and wants their ADHD treated well, a stimulant is the better drug.

So where does guanfacine actually earn its keep? Two places:

1. ADHD complicated by a comorbidity that stimulants worsen: bipolar disorder, active or past substance use, tics, prominent anxiety or agitation, borderline personality disorder, sleep-onset problems. Here guanfacine's liabilities (sedation, modest efficacy) become tolerable trade-offs against a stimulant's liabilities (mania, misuse, tic exacerbation, insomnia).
2. As an adjunct to a stimulant. This is arguably its best-evidenced role. Adding guanfacine to a stimulant beats either alone, blunts stimulant-induced blood-pressure elevation, insomnia, and anxiety, and, reciprocally, the stimulant blunts guanfacine's sedation. The two drugs cover each other's weaknesses.

The thesis of this guide: guanfacine is a tolerability-and-comorbidity play, not an efficacy play. Use it when the clinical situation rewards its specific profile (no abuse potential, calming rather than activating, benign in bipolar illness) and titrate it slowly while watching the heart rate and blood pressure. Prescribed that way, it is a genuinely useful tool. Prescribed as a first-line stimulant substitute for a straightforward ADHD patient, it will mostly disappoint.

Part 1: Indications: Who Is Guanfacine For?

FDA-Approved

• ADHD in children and adolescents (ages 6–17), as the extended-release formulation (Intuniv), approved 2009–2010, both as monotherapy and as adjunct to stimulants.
• Hypertension (the immediate-release tablet, Tenex, is an older antihypertensive; this is guanfacine's original indication and is a non-psychiatric use).

Note that Intuniv is not FDA-approved for adult ADHD. Adult use rests on a single positive RCT (below) and is off-label.

The Evidence-Based Clinical Uses

Pediatric ADHD, the home indication. Two pivotal trials established efficacy vs. placebo. But read the subgroups carefully, because they shape who actually benefits:

• Biederman 2008 (Pediatrics, n=345, doses 2–4 mg): Intuniv beat placebo overall. On subgroup analysis, the signal was strongest in younger children (ages 6–8) and in combined-type ADHD; it was weaker or absent in inattentive-type and in older adolescents.
• Sallee 2009 (JAACAP, n=324, doses 1–4 mg): Intuniv beat placebo in children 12 and under, with no clear advantage in ages 13–17.

The practical read: guanfacine's monotherapy evidence is strongest in younger children with hyperactive/combined-type ADHD. For an inattentive teenager, the case is thinner.

Adult ADHD, off-label, one trial. Iwanami 2020 (J Clin Psychiatry, n=201, Japan) was a 12-week RCT titrating to 4–6 mg/day (mean 5 mg). ADHD-RS-IV scores fell 31→20 on guanfacine vs. 31→24 on placebo (p=0.0005), effect size ~0.5, comparable to atomoxetine, smaller than stimulants. Quality of life did not significantly improve. 20% discontinued for side effects (sedation, hypotension, dizziness). It was manufacturer-funded (Takeda). So: guanfacine works in adults, modestly, at a real dropout cost.

Adjunct to a stimulant, the sweet spot. McCracken 2016 (JAACAP, n=207, ages 7–14) compared stimulant alone, guanfacine alone, and the combination. The combination beat either monotherapy. It produced less blood-pressure elevation than the stimulant alone and less fatigue than guanfacine alone. The benefits were real but not large, and neither drug fully cancelled the other's side effects, but there was no meaningful downside. If a patient is on a stimulant and needs more coverage (or is bothered by stimulant-driven insomnia, anxiety, or blood pressure), adding guanfacine is well-supported.

Reasonable Off-Label Niches

These are areas where guanfacine (or its cousin clonidine) is used clinically, mostly on weaker evidence:

• Tic disorders: alpha-2 agonists suppress tics; useful when ADHD and tics coexist (a setting where stimulants are traditionally feared, though modern data suggest stimulants are safer for tics than once thought).
• ADHD + substance use disorder: no abuse potential, no striatal dopamine; a rational choice when a controlled substance is unwise.
• ADHD + bipolar disorder: small studies support alpha-2 agonist safety in bipolar illness; guanfacine does not carry the mania-induction concern that noradrenergic agents (atomoxetine, stimulants) do.
• Anxiety / agitation: dosed in the daytime for a calming effect.
• Opioid and alcohol withdrawal, nicotine cessation: alpha-2 agonists blunt autonomic withdrawal (clonidine has more evidence here).
• Autism-related irritability, borderline self-harm urges: small/adjunctive data, mostly clonidine.
• Symptom relief odds and ends: SSRI-induced sweating, clozapine-induced hypersalivation, hot flashes, restless legs.

Where Guanfacine Fails or Doesn't Belong

• PTSD. Do not use it. The one RCT (Neylan 2006, Am J Psychiatry, mean dose 2.4 mg) found guanfacine no better than placebo for PTSD, with more side effects (somnolence, lightheadedness, dry mouth). Prazosin (an alpha-1 blocker, different mechanism) is the alpha-adrenergic agent with actual PTSD evidence, especially for nightmares.
• Monotherapy for uncomplicated ADHD in a stimulant-eligible patient: you're leaving efficacy on the table.

Part 2: Before You Start: Workup and Candidacy

Guanfacine's workup is short and centers on the cardiovascular system, because it is an antihypertensive: it lowers heart rate and blood pressure.

Baseline Assessment

Who Is a Poor Candidate?

• Patients with a history of hypotension, syncope, or falls (the additive BP/HR drop can be dangerous).
• Baseline QTc prolongation or significant arrhythmia: guanfacine produced modest QTc prolongation in the adult trial.
• Frail or elderly patients, in whom bradycardia and hypotension are less well tolerated (and who were not represented in the pediatric-heavy trial base).
• Patients who need a rapid response: guanfacine takes 2–5 weeks to build; it is the wrong drug for someone who needs relief this week.
• Patients who cannot tolerate any sedation and cannot dose around it.

A patient already on an antihypertensive is not automatically excluded (most can continue both drugs with close BP monitoring and PCP coordination) but it demands attention.

Part 3: How to Start and Dose

Formulations

• Intuniv (extended-release): The FDA-approved, preferred formulation for ADHD. Once-daily dosing. Now available generically and affordably.
• Tenex (immediate-release): The older antihypertensive tablet. Effective but not the ADHD-preferred product; ER gives smoother levels and better tolerability.
• Half-life: 16–18 hours in adults (shorter in children), which is what makes reliable once-daily dosing feasible, a real advantage over clonidine, whose ~12-hour half-life often forces twice-daily dosing.

A bioavailability trap you must respect: the ER form is only 60–75% as bioavailable as the IR form. Roughly, 3 mg IR ≈ 4 mg ER. Do not assume milligram-for-milligram equivalence when switching between Tenex and Intuniv, or you will under- or over-dose.

Starting Dose and Titration

Children/adolescents (Intuniv ER)

• Start 1 mg once daily.
• Titrate by 1 mg per week based on tolerability and response.
• Typical effective range 2–4 mg/day (studied 1–4 mg).
• Dose by weight where relevant (pediatric labeling scales the target to weight; roughly 0.05–0.12 mg/kg/day territory), but in practice the weekly-titration-to-effect approach works.

Adults (off-label, per Iwanami)

• Start 1 mg/day, titrate 1 mg/week over ~5 weeks.
• Target 4–6 mg/day (mean achieved 5 mg/day).

The governing rule for everyone: start low, go up slowly, and let tolerability set the pace. Guanfacine's side effects (sedation, hypotension, dizziness) cluster during initiation and titration, are dose-related, and often ease with time. Rushing the titration is the main self-inflicted cause of dropout.

When to Dose

Time the dose to the effect you want:

• Daytime sedation is the problem: dose in the evening. The long half-life carries coverage into the next day while the sedative peak occurs during sleep.
• You're targeting anxiety or agitation: dose during the day to use the calming effect when it's needed.

Because the half-life is long, once-daily dosing (at whichever time suits the patient) is appropriate for most.

The Food Interaction: Counsel On It

This is guanfacine-specific and clinically real: a high-fat meal raises guanfacine ER exposure substantially, roughly a 75% jump in peak concentration (Cmax) and a 40% rise in total exposure (AUC). The consequence is more fatigue and hypotension. The fix is not "take it fasting" so much as consistency: take it the same way relative to food every day, and avoid dosing right after a heavy, fatty meal. (For contrast: clonidine ER and atomoxetine have no meaningful food interaction, which can be a reason to prefer them in a patient who can't keep meal timing consistent.)

Part 4: Monitoring

Guanfacine requires no blood levels and no routine labs. The monitoring is cardiovascular and clinical.

On the QTc: the adult RCT showed a modest QTc prolongation vs. placebo, and, notably, EKG changes were still detectable in ~2% of patients two weeks after discontinuation. This is not a reason to avoid the drug in a low-risk patient, but it does argue for a baseline ECG (and caution) in anyone with pre-existing QTc concern, known cardiac disease, or on other QT-prolonging agents.

Part 5: Side Effects and How to Manage Them

The governing principle mirrors most alpha-2 agonists: side effects are dose-related, front-loaded to the titration period, and often ease with time, but they are common enough that tolerability, not efficacy, is the usual reason guanfacine gets stopped.

CNS: Sedation, Somnolence, Fatigue (the Big One)

This is guanfacine's defining liability. On monotherapy, sedation/somnolence/fatigue runs 47–63% in pediatric trials (vs. ~11% on placebo). It is the single most common reason patients quit.

Management:

• Move the dose to the evening so the peak sedation lands during sleep.
• Slow the titration: much of the sedation eases over days to weeks if you don't rush.
• Combine with a stimulant. This is striking and worth memorizing: sedation drops from 59% on guanfacine monotherapy to ~11% when a stimulant is added. The stimulant's activation directly offsets guanfacine's sedation. If a patient needs guanfacine but can't tolerate the drowsiness and can safely take a stimulant, the combination is often better than either alone.
• Reassure that it is dose-related and usually improves.

Cardiovascular: Hypotension, Bradycardia, QTc

Guanfacine is an antihypertensive; these effects are on-target, not idiosyncratic.

• Hypotension and dizziness drove much of the 20% dropout in the adult trial.
• Bradycardia: check the pulse, not just the cuff.
• QTc prolongation: modest, but real (see Monitoring).

Management:

• Titrate slowly: most cardiovascular symptoms are dose- and titration-related.
• Check HR/BP at every increase.
• Coordinate with the PCP if the patient is on antihypertensives; the effects are additive.
• Caution in the elderly and frail, in whom a drop in BP or HR is more consequential (falls, syncope).
• On discontinuation, taper to avoid rebound hypertension (see Part 6).

GI

• Constipation: manage with a standard bowel regimen (fluids, fiber, an osmotic laxative if needed).
• Dry mouth: common to the class; usually mild.

The Paradoxical Upside

Some of guanfacine's "side effects" are useful elsewhere. Its alpha-2 agonism means it can simultaneously relieve tics, SSRI-induced sweating, clozapine-induced hypersalivation, hot flashes, and restless legs. In a patient with ADHD plus one of these, guanfacine may earn double duty.

Part 6: Overdose, Toxicity, and Discontinuation Safety

Guanfacine has no boxed warning. Its safety concerns are pharmacologically predictable extensions of an alpha-2 agonist antihypertensive.

Overdose

Overdose produces exaggerated on-target effects: bradycardia, hypotension, sedation/CNS depression (drowsiness progressing to lethargy). In children especially, ingestion can cause pronounced somnolence and bradycardia. Management is supportive: this is an ED evaluation with cardiac monitoring; there is no specific antidote and treatment is directed at hemodynamics and airway. Because guanfacine lowers heart rate and blood pressure, co-ingestion with other CNS depressants or antihypertensives compounds the risk.

Rebound Hypertension: The One to Remember

Abrupt discontinuation of an alpha-2 agonist can cause rebound hypertension. This is best documented with clonidine, but the mechanism (loss of central sympatholytic tone) plausibly applies to guanfacine, and the prudent assumption is that it does: guanfacine's longer half-life may soften but does not eliminate the risk.

QTc Persistence

Worth restating: after stopping guanfacine, QTc changes lingered in ~2% of patients at two weeks. For most patients this is clinically irrelevant, but in anyone with cardiac risk or on other QT-prolonging drugs, keep it in mind around discontinuation as well as initiation.

Part 7: Drug Interactions

Guanfacine Is a CYP3A4 Substrate

Its levels are moved by CYP3A4:

• CYP3A4 inhibitors raise guanfacine levels: more sedation and hypotension. Psychiatric-relevant culprits include fluvoxamine and nefazodone (plus the usual azole antifungals, macrolides, ritonavir, grapefruit). Consider a lower guanfacine dose and monitor when co-prescribing.
• CYP3A4 inducers lower guanfacine levels: possible loss of efficacy. Carbamazepine is the classic psychiatric example (also phenytoin, rifampin, St. John's wort). You may need a higher guanfacine dose.

Mirtazapine: A Specific Caution

Mirtazapine is an alpha-2 antagonist, pharmacologically opposite to guanfacine. Case reports describe hypertensive urgency when the two are combined (Abo-Zena 2000). Avoid the combination or use it cautiously with close BP monitoring.

Additive Cardiovascular Depressants

• Other antihypertensives (beta-blockers, other alpha-2 agonists, calcium-channel blockers): additive hypotension/bradycardia. Combinable with monitoring and PCP coordination, but respect the additive effect.
• Other CNS depressants (alcohol, benzodiazepines, opioids, sedating antihistamines): additive sedation.
• Other QT-prolonging agents: additive QTc effect: factor guanfacine's modest contribution into a patient already on QT-prolonging drugs.

The Beneficial "Interaction": Stimulants

The most clinically important combination is a good one. Guanfacine plus a stimulant (McCracken 2016) outperforms either alone, with each drug offsetting the other's side effects: the stimulant reduces guanfacine's sedation (59% → 11%), and guanfacine reduces the stimulant's blood-pressure elevation, anxiety, and insomnia. Guanfacine is the preferred agent for augmenting a stimulant, with better trial evidence than atomoxetine (whose safety combined with stimulants is less established).

Part 8: Special Populations

Pregnancy and Lactation

Human data are limited. There is no robust signal of major teratogenicity, but the evidence base is thin, and guanfacine is not a drug with a reassuring pregnancy dataset. Weigh the benefit against the modest efficacy: ADHD is rarely an emergency that mandates pharmacotherapy in pregnancy, so for many patients the reasonable move is to defer or minimize. If treatment is necessary, individualize with the obstetric team, and remember the maternal cardiovascular effects (hypotension, bradycardia). Lactation data are sparse; decide case-by-case with pediatric input. Do not represent guanfacine as "known safe" in pregnancy or breastfeeding; the honest answer is "insufficiently studied."

Elderly / Frail

Guanfacine's trial base is overwhelmingly pediatric. In older or frail patients, the cardiovascular effects (bradycardia, hypotension, QTc prolongation, fall risk) carry more weight and are less well characterized. Start lower, go slower, monitor HR/BP closely, and consider a baseline ECG. Often not the best choice in this population.

Renal / Hepatic

The pooled notes don't give clean guanfacine-specific renal/hepatic dosing figures, so don't invent them. Guanfacine is metabolized by CYP3A4 (hepatic) with renal elimination of drug and metabolites, so significant renal or hepatic impairment can raise exposure: start low, titrate cautiously, and monitor for exaggerated hypotension/sedation. Coordinate with the relevant specialist for advanced organ impairment.

Pediatric

This is guanfacine's FDA home (ages 6–17). Efficacy is best supported in younger children with hyperactive/combined-type ADHD; the signal weakens in inattentive-type and in adolescents. Half-life is shorter in children than adults, which can matter for dosing coverage. The alpha-2 agonists (guanfacine, clonidine) have small studies supporting safety in the psychiatrically comorbid child (bipolar illness, autism irritability), a genuine advantage over atomoxetine's noradrenergic mania concern.

Part 9: Discontinuation

Guanfacine is simpler to stop than lithium or an antidepressant, but it is not a stop-anytime drug because of the rebound-hypertension risk.

• Taper, don't stop abruptly. A ~2-week taper (as used in the adult trial) is a reasonable default; slower is fine, especially in patients on higher doses or with cardiovascular risk.
• Monitor BP through and just after the taper: rebound hypertension is the specific hazard.
• If ADHD symptoms were the target and you're switching agents, there's no psychiatric withdrawal syndrome to fear (unlike lithium's rebound mania); the concern is purely cardiovascular.

Part 10: Guanfacine vs. the Alternatives

vs. Stimulants

Stimulants win on efficacy (effect size 0.8–0.9 vs. guanfacine's ~0.5) and speed (rapid vs. 2–5 weeks). Guanfacine wins on abuse potential (none vs. real), controlled-substance status (unscheduled, refillable vs. Schedule II), and suitability in specific comorbidities stimulants worsen. It's calming rather than activating. The two are not really competitors so much as tools for different situations, and they combine well.

vs. Clonidine (Kapvay)

The other alpha-2 agonist. Roughly equal efficacy for ADHD. Guanfacine's advantages: less sedating (its main selling point) and a longer half-life (16–18 h vs. 12 h, for easier once-daily dosing). Clonidine's advantages: more research in psychiatric comorbidities (PTSD, mania, BPD, autism irritability), a transdermal patch option (which reduces sedation and dry mouth), and no food interaction. For a straightforward ADHD patient bothered by clonidine's drowsiness, guanfacine is the natural switch; for a patient where the comorbidity is the main event, clonidine may have more supporting data.

vs. Atomoxetine (Strattera)

Similar effect size (~0.5 vs. 0.4–0.6). Both are non-controlled, non-abusable. Differences: atomoxetine is noradrenergic (raises HR/BP, carries a pediatric suicidality warning, and has a theoretical mania-induction risk that makes it a poor choice in bipolar illness) while guanfacine is sympatholytic (lowers HR/BP, calming, benign in bipolar illness). Atomoxetine's interactions run through CYP2D6 (fluoxetine, paroxetine, bupropion, poor metabolizers); guanfacine's through CYP3A4. Choose by the comorbidity: bipolar disorder or a need for calming favors guanfacine; comorbid anxiety or a need to avoid sedation/hypotension often favors atomoxetine.

Mechanism: The Short Version

Guanfacine is a selective alpha-2A adrenergic agonist. In the periphery it reduces central sympathetic outflow, which is why it lowers heart rate and blood pressure (its original antihypertensive action).

Its ADHD benefit is a prefrontal-cortex story. By stimulating postsynaptic alpha-2A receptors on prefrontal pyramidal neurons, guanfacine strengthens the neural signals underlying working memory, attention regulation, and impulse control; in Amy Arnsten's model, it "closes" the ion channels that otherwise leak away the network connectivity these neurons need. This is the opposite end of the mechanism from stimulants, which flood the synapse with catecholamines; guanfacine instead makes existing prefrontal signaling more efficient. Effects on the locus coeruleus noradrenergic system contribute to the reduction in inattention, hyperactivity, and impulsivity.

Two mechanistic facts explain the clinical feel of the drug: the alpha-2A action is why it is calming rather than activating (and useful for anxiety, tics, and withdrawal states), and its slow, tonic strengthening of prefrontal circuits is why the benefit builds over 2–5 weeks rather than switching on like a stimulant.

Pharmacokinetics: half-life 16–18 h in adults (shorter in kids); CYP3A4-metabolized; ER bioavailability 60–75% of IR (3 mg IR ≈ 4 mg ER); absorption meaningfully increased by high-fat meals.

The Bedside Cheat Sheet